Pfizer Inc. [NYSE: PFE] loss -0.23% or -0.08 points to close at $34.07 with a heavy trading volume of 57825096 shares. The company report on September 12, 2023 at 7:30 PM that European Medicines Agency Validates Type II Variation for Astellas’ XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence.
Application based on results from Phase 3 EMBARK trial, which showed XTANDI plus leuprolide reduced risk of metastasis or death by 58%.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the European Medicines Agency (EMA) has validated its Type II variation for XTANDI® (enzalutamide) for the treatment of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR) who are unsuitable for salvage-radiotherapy.
It opened the trading session at $34.06, the shares rose to $34.415 and dropped to $33.81, the range by which the price of stock traded the whole day. The daily chart for PFE points out that the company has recorded -15.61% loss over the past six months. However, it is still -1.58% lower than its most recent low trading price.
If we look at the average trading volume of 24.44M shares, PFE reached to a volume of 57825096 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Pfizer Inc. [PFE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $44.09 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 17, 2023.
The Average True Range (ATR) for Pfizer Inc. is set at 0.66, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 2.47. The Price to Book ratio for the last quarter was 1.94, with the Price to Cash per share for the same quarter was set at 7.91. Price to Free Cash Flow for PFE in the course of the last twelve months was 18.08 with Quick ratio for the last quarter at 1.80.
Trading performance analysis for PFE stock
Pfizer Inc. [PFE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.53. With this latest performance, PFE shares dropped by -3.97% in over the last four-week period, additionally sinking by -15.61% over the last 6 months – not to mention a drop of -26.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 33.28, with the RSI for the last a single of trading hit 29.30, and the three-weeks RSI is set at 36.23 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 35.79, while it was recorded at 34.08 for the last single week of trading, and 40.86 for the last 200 days.
Pfizer Inc. [PFE]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +37.43 and a Gross Margin at +61.89. Pfizer Inc.’s Net Margin is presently recorded at +31.26.
Return on Total Capital for PFE is now 29.59, given the latest momentum, and Return on Invested Capital for the company is 25.39. Return on Equity for this stock inclined to 36.29, with Return on Assets sitting at 16.57. When it comes to the capital structure of this company, Pfizer Inc. [PFE] has a Total Debt to Total Equity ratio set at 40.82. Additionally, PFE Total Debt to Total Capital is recorded at 28.99, with Total Debt to Total Assets ending up at 19.80. Long-Term Debt to Equity for the company is recorded at 37.09, with the Long-Term Debt to Total Capital now at 26.34.
Reflecting on the efficiency of the workforce at the company, Pfizer Inc. [PFE] managed to generate an average of $377,904 per employee. Receivables Turnover for the company is 8.95 with a Total Asset Turnover recorded at a value of 0.53.Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 2.10.
An analysis of Institutional ownership at Pfizer Inc. [PFE]
There are presently around $132.87 billion, or 70.5% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in PFE stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in PFE stock with ownership which is approximately 5.7381%.
